Gaurav Aggarwal
CIK: 0001551965
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Aug 25, 2025UNCY
Unicycive Therapeutics, Inc.
Disposition(D)IndirectSeries A-2 Prime Preferred Stock
3.2K shares at avg. $1000.00- - Aug 25, 2025UNCY
Unicycive Therapeutics, Inc.
Conversion(C)Indirect652.9K shares- - Jul 28, 2025UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectStock Options
21.2K shares- - May 21, 2025GERN
GERON CORP
Award(A)DirectStock Option (right to buy)
180K shares- - Feb 18, 2025UNCY
Unicycive Therapeutics, Inc.
Conversion(C)Indirect1.4M shares- - Feb 18, 2025UNCY
Unicycive Therapeutics, Inc.
Disposition(D)IndirectSeries A-2 Prime Preferred Stock
686 shares at avg. $1000.00- - Oct 9, 2024UNCY
Unicycive Therapeutics, Inc.
Conversion(C)Indirect5.5M shares- - Oct 9, 2024UNCY
Unicycive Therapeutics, Inc.
Disposition(D)IndirectSeries A-2 Prime Preferred Stock
2.7K shares at avg. $1000.00-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 25, 2025 |  UNCY Unicycive Therapeutics, Inc. | Disposition(D) Series A-2 Prime Preferred Stock | 3,199 | $1000.00 | - | Indirect |
| Aug 25, 2025 | UNCY Unicycive Therapeutics, Inc. | Conversion(C) | 652,900 | - | - | Indirect |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | Award(A) Stock Options | 21,200 | - | - | Direct |
| May 21, 2025 |  GERN GERON CORP | Award(A) Stock Option (right to buy) | 180,000 | - | - | Direct |
| Feb 18, 2025 | UNCY Unicycive Therapeutics, Inc. | Conversion(C) | 1,400,000 | - | - | Indirect |
| Feb 18, 2025 | UNCY Unicycive Therapeutics, Inc. | Disposition(D) Series A-2 Prime Preferred Stock | 686 | $1000.00 | - | Indirect |
| Oct 9, 2024 | UNCY Unicycive Therapeutics, Inc. | Conversion(C) | 5,500,000 | - | $0 | Indirect |
| Oct 9, 2024 | UNCY Unicycive Therapeutics, Inc. | Disposition(D) Series A-2 Prime Preferred Stock | 2,695 | $1000.00 | - | Indirect |
1-8 of 8 transactions
About Aggarwal Gaurav
Aggarwal Gaurav (SEC CIK 0001551965) files insider reports with the SEC as Director of Unicycive Therapeutics, Inc. (UNCY) and Director of GERON CORP (GERN).
Signal8 holds 5 ownership filings by Aggarwal Gaurav, all Form 4s, filed between Oct 10, 2024 and Aug 26, 2025. Those filings report 8 transactions, from Oct 9, 2024 to Aug 25, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Aggarwal Gaurav's filings is in LOS ALTOS, CA.
Recent filings by Aggarwal Gaurav
- Aug 25, 2025: Disposition to issuer transaction of UNCY derivative securities (Form 4, code D).
- Aug 25, 2025: Conversion of UNCY shares (Form 4, code C).
- Jul 28, 2025: Grant or award of UNCY derivative securities (Form 4, code A).
- May 21, 2025: Grant or award of GERN derivative securities (Form 4, code A).
- Feb 18, 2025: Conversion of UNCY shares (Form 4, code C).
Other insiders filing for Unicycive Therapeutics, Inc. (UNCY)
- Manning Meredith, Director
- Kenkare-Mitra Sara, Director
- Laumas Sandeep, Director
- Gupta Shalabh K., CEO
- Gupta Pramod, EVP, Pharmaceuticals and BD
- Townsend John, CFO